Adherence to Botulinumtoxin Treatment: A 2-year Retrospective Claims Database Analysis (P12-11.008)

Abstract

<h3>Objective:</h3> To describe treatment dynamics and persistence with botulinumtoxin (BoNT) over 2 years in a retrospective longitudinal study. <h3>Background:</h3> Understanding the use of BoNT in clinical practice is essential for improving clinical care. Real-world evidence on long-term persistence with BoNT therapy is limited. <h3>Design/Methods:</h3> This study assessed medical claims data from the IBM MarketScan database among patients with a first medical claim for BoNT (not product specific) between October 2016 and October 2019. The index date was the day of the first BoNT administration, and a 1-year washout period before this date was used to identify incident BoNT use. On-label indications were defined as those approved for abobotulinumtoxinA. Six cohorts were analyzed: 1, all patients; 2, all patients, excluding those with off-label indications at the index date; 3, all patients with on-label diagnosis during the study period; and 4, 5 and 6, all patients with diagnosis of stroke, migraine and bladder dysfunction, respectively, before the index date. The number of treatments in the 2-year follow-up period and persistency (120-day look forward from treatment date; 80th percentile value of days to next treatment) were evaluated. <h3>Results:</h3> Across all cohorts (cohort [n]: 1 [19 711], 2 [5741], 3 [3238], 4 [611], 5 [7778] and 6 [1791]), 18.8–46.9% of patients received only one injection. Proportions of patients receiving three to eight injections remained consistent, with 0.3–15.7% receiving eight injections. Mean number of treatments across cohorts was 2.1–4.7, and time between treatments (80th percentile) was 105–319 days. <h3>Conclusions:</h3> In this retrospective longitudinal real-world study, there was a large drop-off in the proportion of patients receiving BoNT treatment after first injection, with few patients receiving eight injections over 2 years in accordance with the standard treatment regimen. These data are limited in providing the underlying reasons for the drop-off; further research is warranted. <b>Disclosure:</b> Dr. Simpson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan. Dr. Simpson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. Mr. Bouchard has received personal compensation for serving as an employee of Ipsen. Mr. Bouchard has stock in Ipsen. Dr. Page has received personal compensation for serving as an employee of Ipsen. Dr. Page has received stock or an ownership interest from Ipsen. Dr. Spurden has received personal compensation for serving as an employee of IPSEN. Mr. Goldfarb has nothing to disclose. Atul T. Patel, 15908 has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Revance. Atul T. Patel, 15908 has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Atul T. Patel, 15908 has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen. Atul T. Patel, 15908 has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan/Abbvie. Atul T. Patel, 15908 has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for IPSEN. The institution of Atul T. Patel, 15908 has received research support from Allergan. The institution of Atul T. Patel, 15908 has received research support from Revance. The institution of Atul T. Patel, 15908 has received research support from IPSEN.